Clinical trial
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With…
NCT00006240 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00006240 |
|---|---|
| Title | Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia |
| Official title | A Pilot Study of Phenylbutyrate, Dexamethasone and GM-CSF in Refractory or Relapsed t(8;21) Acute Myeloid Leukemia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | sargramostim, dexamethasone, oral sodium phenylbutyrate |
| Start date | Oct 1, 2000 |
| Completion | Aug 1, 2001 |
| First posted | Jul 28, 2003 |
| Last update posted | Apr 28, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: